Legal & Corporate Governance
Intellectual Property & Patent Estate
The underlying chemical architecture, deep eutectic solvent (DES) formulations, and "Moisture-Activated Phase Inversion" methodologies constitute the exclusive proprietary property of Anthos Biotechnologies, Inc.
PATENT NOTICE: The technology disclosed herein is subject to United States Patent Application No. 63/950,692, with concurrent filings under the Patent Cooperation Treaty (PCT) for global protection.
This electronic document serves as statutory notice under 35 U.S.C. § 287(a). Anthos maintains a policy of vigorous enforcement regarding its intellectual property rights. Any unauthorized replication, reverse engineering, or commercialization of the DES carrier system will result in immediate legal action.
1. Terms of Access & Allocation
Access to the Anthos platform and the "Secure Allocation" protocol is governed by these Terms. The Protocol is a limited-access reservation system designed to manage inventory constraints inherent to our manufacturing process.
Reservation of Rights: Submission of data does not constitute a binding contract of sale. Anthos reserves the absolute right to vet prospective clients and allocate inventory at its sole discretion, prioritizing institutional partners and pre-qualified entities.
2. Regulatory Classification & FDA Disclaimer
The formulations described herein are classified as cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act). While the mechanism of action utilizes biomimetic principles, the product is intended solely for dermatological appearance enhancement.
- Non-Pharmacological Status: This product is not a drug as defined in 21 U.S.C. § 321(g)(1). It is not intended to diagnose, mitigate, treat, cure, or prevent any disease state.
- Structure/Function Claims: References to "antioxidant stability," "cellular preservation," and "radical scavenging" refer to in vitro chemical assays of the raw material (Cyanidin-3-Glucoside) and its solvent matrix, not to physiological endpoints in the human body.
3. Forward-Looking Statements (Safe Harbor)
This website contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding future clinical trials, patent issuance, manufacturing capabilities, and strategic partnerships are subject to risks and uncertainties.
Actual results may differ materially from those indicated. These statements are made as of the date herein, and Anthos assumes no obligation to update them, except as required by law.
4. Data Sovereignty & Privacy
Anthos employs enterprise-grade data security protocols. Information collected via the Protocol is encrypted and stored on secure, sovereign servers. We strictly adhere to GDPR and CCPA compliance standards. Client data is utilized exclusively for internal allocation logic and is never monetized or distributed to third-party aggregators.
5. Governing Law & Jurisdiction
These Terms, and any disputes arising out of or related to these Terms or the use of the Site, shall be governed by the laws of the State of Delaware. Any legal action or proceeding relating to your access to, or use of, the Site shall be instituted exclusively in the Court of Chancery of the State of Delaware.